NCT04291755
Development and Analysis of a Stool Bank for Cancer Patients
StatusEnrolling by Invitation
PhaseNot specified
SponsorPersephone Biosciences
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 4 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Trial status changed: Recruiting → Enrolling by Invitation
- Eligibility criteria expanded, about 6 words
- Site details revised at 2 of 2 sites
- Notable Trial status: Active, Not Recruiting to Recruiting
- Primary and study completion dates: Dec 31, 2022 to Dec 31, 2028
- Site details revised at 2 of 2 sites
- Notable Primary and study completion dates pushed to Dec 31, 2022
- Trial status: Recruiting to Active, Not Recruiting
- Site details revised at 2 of 2 sites
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Checkpoint inhibitor response
Timeframe: 6-12 months
Arms and interventions
Checkpoint inhibitor therapy
Patients will be administered a checkpoint inhibitor therapy, including but not limited to pembrolizumab, nivolumab, ipilimumab, and atlizumab, at the standard dosing regimen prescribed by their physician. Stool, blood, and urine samples will be collected from patients prior to start of treatment, and at 4 more timepoints over the next 12 months.
Drugs: Pembrolizumab Injection
Sites
2 sites in 1 country